Japanese generics firm Sawai Pharmaceutical has continued to benefit from the domestic supply stoppages that set back some of its rivals in its financial second quarter ended 30 September 2021, but its US performance has been hampered by increased competitor launches.
Year-on-year, net sales in H1 increased by 7.9% across the board to ¥97
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?